(Reuters) – The following are some of the
main factors expected to affect Swiss stocks on Monday.
SWISS NATIONAL BANK
The Swiss National Bank said on Friday its vice-chairman
Jean-Pierre Danthine – who helped introduce a cap on the value
of the Swiss franc – will retire in June, launching a succession
search as the SNB faces down renewed pressure on the franc.
For more, click on:
ROCHE
Swiss drugmaker Roche said the European Union has approved
the use of its drug RoActemra in patients with early rheumatoid
arthritis.
For more, click on:
COMPANY STATEMENTS
* Novartis said its drug Ultibro Breezhaler
reduced the rate of moderate-to-severe flare-ups in patients
with moderate-to-severe chronic obstructive pulmonary disease
(COPD) by 31 percent compared to GlaxoSmithKline’s
Seretide, in a head-to-head study. The drug was also better at
improving lung function.
* Roche said it had launched an ALK inhibitor
capsule, Alecensa, in Japan.
* Basilea said the U.S. Food and Drug
Administration has accepted for filing the New Drug Application
for isavuconazole submitted by its license partner Astellas
Pharma Inc..
* Lindt & Spruengli said Ralf Fallegger, former
member of its extended group management, would become a member
of the group management with immediate effect.
* Swisscom said it had concluded the takeover of
PubliGroupe.
* PubliGroupe said it would hold an extraordinary
general meeting on Oct 24 to elect new board of directors as
proposed by Swisscom.
* HIAG Immobilien posted net income of 24.6 million
Swiss francs in the first half.
* Partners Group said it has completed the purchase
of a real estate portfolio of retail and office properties in
Finland and Sweden on behalf of its clients, via a secondary
transaction.
ECONOMY
* Unadjusted and adjusted unemployment rates for August
expected at 0545 GMT
* Weekly SNB sight deposits at 0700 GMT
* CPI data for August expected at 0715 GMT
* Swiss retail sales for July due at 0715 GMT